Cpl Life Sciences US

We'd like to wish our colleague Christopher Jimenez who celebrated his birthday in August a very #happybirthday, and we hope you enjoyed your birthday day off! 🥳 🎂 #Cpl #workthefuture #birthdaywishes

❗ Exciting Times for Ascendis Pharma as they Secure FDA Approval for Yorvipath After a Long Road of Challenges! 👍 Ascendis Pharma’s recent FDA approval for Yorvipath (palopegteriparatide), its breakthrough hormone replacement therapy for hypoparathyroidism, marks a significant milestone not just for the company, but for the entire pharmaceutical industry. The approval, following a challenging 15-month delay, underscores the company’s resilience and commitment to advancing healthcare in rare disease treatment. Ascendis Pharma’s perseverance in overcoming regulatory hurdles highlights the need for skilled professionals who can navigate complex challenges in drug development and regulatory affairs. As Yorvipath prepares for its U.S. launch, the company will likely seek to expand its teams in manufacturing, quality control, regulatory compliance, and commercialization to ensure a successful rollout. “We have worked on this product for nearly 10 years,” Ascendis CEO Jan Møller Mikkelsen said during a conference call Monday. This decade-long commitment reflects the dedication and resilience of the Ascendis team in their mission to deliver life-changing therapies to patients in need. Despite the setbacks, the company remained focused, and now the finish line is finally in sight. This approval is a beacon of hope for the estimated 70,000 to 90,000 people in the U.S. suffering from hypoparathyroidism, a condition that disrupts the body’s delicate balance of calcium and phosphorus. Yorvipath, offering continuous 24-hour dosing, demonstrated its effectiveness in clinical trials by significantly improving calcium levels and reducing the need for conventional therapies. 💡 For Ascendis Pharma this is a story of innovation, resilience, and hope for patients with unmet medical needs. We are grateful for the advancements in technology that make such breakthroughs possible and look forward to seeing Yorvipath transform lives in the near future. [Read the full article here] https://lnkd.in/ehyhYkcA ❓ As we witness these exciting developments in the industry, what do you think will be the key factors for success in launching innovative therapies like Yorvipath? Whether you’re a seasoned professional or just starting in the pharma and biotech fields, I’d love to hear your insights. Let’s discuss how these trends might shape the future of our industry and the opportunities they create for top talent. #PharmaIndustry #Biotech #DrugDevelopment #ClinicalOperations #Regulatory #PharmaceuticalNews

❤️ Heart Care Revolution! Huge Achievements have been reached with the First Successful Implantation of BiVACOR's Total Artificial Heart (TAH). We are thrilled to share a groundbreaking achievement in the field of cardiac care! The Texas Heart Institute and BiVACOR have successfully implanted the BiVACOR Total Artificial Heart (TAH) in a human for the first time. This innovative device, designed to replace both ventricles of a failing heart, represents a beacon of hope for patients with severe heart failure awaiting transplants. 👩🔬 This milestone not only showcases the incredible advancements in med tech but also brings us one step closer to providing life-saving solutions for countless individuals. The BiVACOR TAH, with its advanced design and magnetic levitation technology, promises to transform the future of heart failure therapy. We are immensely proud of the dedicated teams at The Texas Heart Institute, BiVACOR, Baylor College of Medicine, and CHI St. Luke's Health - Baylor St. Luke's Medical Center for their unwavering commitment to improving patient outcomes. Together, they are pioneering a new era in cardiac medicine and offering renewed hope to those in need. 🗓 This is a huge testament to why our industry work is so rewarding and how leveraging partnerships can speed up timelines for patients who need it most, AMAZING WORK! #Innovation #Healthcare #MedicalBreakthrough #HeartFailure #CardiacCare #Biotechnology" Read more below and share your thoughts! https://lnkd.in/dRiUxxPw

We love receiving candidate feedback. Here is an amazing review Aoife Gillespie has recently received! We love hearing about our candidate success stories and placing them into their dream roles within industry. Wishing each and every one of our candidates the best of luck in their new roles! 🌟 #feedbackmatters #testimonial #kudos

In our latest case study, we delve into how CPL Life Sciences US has revolutionized talent acquisition for our clients. Our client, a leading firm in the industry, shares their experience: "What has impressed us is the diversity of candidates Cpl seems to send across. Shortlists tend to have a mixture of backgrounds and skillsets, which is positively recognized internally." Explore how our commitment to diversity and inclusion not only meets but exceeds expectations, providing a rich pool of talent that drives innovation and success. Learn about our strategic approach, unique methodologies, and the tangible benefits our clients experience by partnering with Cpl Life Sciences US. Read the full case study to see how we can transform your talent acquisition process! https://lnkd.in/gZSr2V_B #LifeSciences #CaseStudy

Happy 4th of July to all our clients and candidates in the USA! May this Independence Day be filled with pride, unity, and joy as we celebrate the spirit of freedom and democracy. Tom Hancox Aoife Gillespie Christopher Jimenez Rhys Rowberry #IndependenceDay #LifeSciences #4thofJuly

Exciting News in Alzheimer's Research! Eli Lilly and Company's Kisunla just secured FDA approval for slowing Alzheimer's progression, marking a major milestone in this field. This, along with Leqembi's (Biogen - Eisai US) recent approval, offers renewed hope for millions facing this devastating disease. But the fight's not over! Several other promising therapies are in various stages of development, as highlighted in the table below. Table Link: https://lnkd.in/eTSQH-9V Let's discuss! Share your thoughts and insights on the future of Alzheimer's treatment in the comments. #Alzheimers #ClinicalTrials #HopeforTomorrow #MedTech

Boston’s biotech sector is booming, but there's a worker shortage! While recent layoffs have made headlines, the biggest future issue for Boston’s thriving biotech sector isn’t a lack of jobs. A new report from the Massachusetts Biotechnology Education Foundation highlights a looming worker shortage and emphasizes the need to better recruit local college graduates. 🚀 With over 5,700 job openings yearly and only 61% filled by local grads, MassBioEd is stepping up with internships and apprenticeships. 🌟 Let’s bridge the gap! Join the conversation! Share your thoughts on how we can attract and retain more talent in the life sciences sector in the comments. 🌱💼 #Biotech #LifeSciences #MassBioEd #WorkforceDevelopment #Biotech #LifeSciences #Career Articles: https://lnkd.in/e4VK8WNQ https://lnkd.in/e8kDJBxv

Boston’s biotech sector is booming, but there's a worker shortage! While recent layoffs have made headlines, the biggest future issue for Boston’s thriving biotech sector isn’t a lack of jobs. A new report from the Massachusetts Biotechnology Education Foundation highlights a looming worker shortage and emphasizes the need to better recruit local college graduates. 🚀 With over 5,700 job openings yearly and only 61% filled by local grads, MassBioEd is stepping up with internships and apprenticeships. 🌟 Let’s bridge the gap! Join the conversation! Share your thoughts on how we can attract and retain more talent in the life sciences sector in the comments. 🌱💼 #Biotech #LifeSciences #MassBioEd #WorkforceDevelopment #Biotech #LifeSciences #Career Articles: https://lnkd.in/e4VK8WNQ https://lnkd.in/e8kDJBxv

AI in Life Sciences: Free Expert Insights! 📹 The rise of AI in Med-Tech is transforming the industry! We sat down with top experts to discuss the latest trends & challenges, from regulations to talent check out this session and join the conversation.